← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest quality evidence only (79)Meta-analysis (20)Treatment guideline (4)Phase 3 study (27)Randomized trial (14)Systematic review (14)Clinical trial (677)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR. (2022/12/30) ♡
• Concept of Health in Opinions of Patients Diagnosed with Hepatitis C. (2022/12/30) ♡
• Studies of the symmetric binding mode of daclatasvir and analogs using a new homology model of HCV NS5A GT-4a. (2022/12/29) ♡
• Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts. (2022/12/29) ♡
• Patient-reported outcomes with direct-acting antiviral treatment for hepatitis C in West and Central Africa (TAC ANRS 12311 trial). (2022/12/28) ♡
• Expectations of patients with hepatitis C from family physicians - a Polish example. (2022/12/27) ♡
• The Role of LINC01564, RAMS11, CBX4 and TOP2A in Hepatocellular Carcinoma. (2022/12/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A rare case report of iatrogenic Cushing syndrome caused by direct anti-hepatitis C virus therapy with sofosbuvir/velpatasvir. (2022/12/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Thyroid gland and direct-acting antivirals (DAAs) used to treat chronic hepatitis C. Is it a safe regimen? (2022/12/22) ♡
• Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. (2022/12/21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The impact of treatment on the psychological burden of mothers of children with chronic hepatitis C virus infection: a multicenter, questionnaire survey. (2022/12/21) ♡
• Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy. (2022/12/17) ♡
• Serum Galectin-3 in Hepatitis C Virus Infection Declines after Successful Virus Eradication by Direct-Acting Antiviral Therapy. (2022/12/17) ♡
• Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis. (2022/12/17) ♡
• "Like a pickle that's been unpickled": Emotional, identity and behavioural transformations throughout hepatitis C treatment. (2022/12/12) ♡
• Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors. (2022/12/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis. (2022/12/11) ♡
• Thrombocytopenia and liver disease: pathophysiology and periprocedural management. (2022/12/09) ♡
• Accuracy of noninvasive methods for the diagnosis of liver fibrosis in children with chronic viral hepatitis. (2022/12/09) ♡
• HCV elimination in a Swiss opioid agonist therapy programme - a cohort study. (2022/12/09) ♡
• Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes. (2022/12/09) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. (2022/12/07) ♡
• Lipid Droplet-Associated Proteins Perilipin 1 and 2: Molecular Markers of Steatosis and Microvesicular Steatotic Foci in Chronic Hepatitis C. (2022/12/07) ♡
• Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C. (2022/12/06) ♡
• An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study). (2022/12/05) ♡
• Patient outcomes in public sector hepatitis C treatment programmes: a retrospective cohort analysis across five low- and middle-income countries. (2022/12/05) ♡
• Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients. (2022/12/03) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Minor hepatectomy for hepatocellular carcinoma in a patient with portal hypertension: A case report and review of the literature. (2022/12/02) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Epidemiology of occult hepatitis B and C in Africa: A systematic review and meta-analysis. (2022/12/01) ♡
• Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain. (2022/12/01) ♡
• Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States. (2022/12/01) ♡
• Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C. (2022/12/01) ♡
• Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. (2022/12/01) ♡
• Impact of direct-acting antiviral use for chronic hepatitis C on health care costs in Medicaid: economic model update. (2022/12/01) ♡
• Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection. (2022/12/01) ♡
• Interplay between TGF-β1 and miRNA-122 biomarkers in hepatocellular carcinoma progression in patients with chronic hepatitis C. (2022/12/01) ♡
• Tolloid-like 1 gene variant rs17047200, pretreatment FIB-4, ALBI and PALBI scores as predictors of hepatocellular carcinoma occurrence after directly acting antivirals. (2022/12/01) ♡
• Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience. (2022/12/01) ♡
• Hepatitis C time trends in reported cases and estimates of the hidden population born before 1965, Denmark and Sweden, 1990 to 2020. (2022/12/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Transplant of Kidneys From Hepatitis C Virus-Positive Donors To Hepatitis C Virus-Negative Recipients: A Retrospective Study and Systematic Review. (2022/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. [Clinical Features and Treatment for Cholangiolocellular Carcinoma(CoCC)-Report of Three Cases]. (2022/12/01) ♡
• LncRNA NEAT1 regulates HCV-induced Hepatocellular carcinoma by modulating the miR-9-BGH3 axis. (2022/12/01) ♡
• [Cryoglobulinemic vasculitis]. (2022/12/01) ♡
• Assessment of HCV-RNA test results and access rates to antiviral treatment in patients with anti-HCV positivity-a 10-year analysis. (2022/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project. (2022/11/30) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Chronic Hepatitis C: Pathophysiology and Clinical Issues. (2022/11/29) ♡
• Real-world impact of a subsidy decision of sofosbuvir-velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes. (2022/11/29) ♡
• Distinct Expression Patterns of Genes Coding for Biological Response Modifiers Involved in Inflammatory Responses and Development of Fibrosis in Chronic Hepatitis C: Upregulation of SMAD-6 and MMP-8 and Downregulation of CAV-1, CTGF, CEBPB, PLG, TIMP-3, MMP-1, ITGA-1, ITGA-2 and LOX. (2022/11/27) ♡
• Development and Validation of a Risk Prediction Tool to Identify People at Greater Risk of Having Hepatitis C among Drug Users. (2022/11/25) ♡
• Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project. (2022/11/25) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.